Xuelian Wei
- Virology top 0.5%
- HIV Research and Treatment 14
- Emergency Medicine top 0.5%
- HIV-related health complications and treatments 10
- Infectious Diseases top 0.5%
- HIV/AIDS drug development and treatment 20
- HIV/AIDS Research and Interventions 10
- Hepatology top 10%
- Nephrology top 10%
- Renal Diseases and Glomerulopathies 8
-
- Platelet Disorders and Treatments 3
-
- Pharmacological Effects and Toxicity Studies 3
-
- Systemic Lupus Erythematosus Research 3
Xuelian Wei
31 papers receiving 2.0k citations
Hit Papers
Peers
Comparison fields: 5 of 87
- Virology 1.0k
- Emergency Medicine 886
- Infectious Diseases 1.6k
- Hepatology 113
- Nephrology 72
Countries citing papers authored by Xuelian Wei
This map shows the geographic impact of Xuelian Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xuelian Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xuelian Wei more than expected).
Fields of papers citing papers by Xuelian Wei
This network shows the impact of papers produced by Xuelian Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xuelian Wei. The network helps show where Xuelian Wei may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Xuelian Wei, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathybreakdown → | 2024 | 51 |
| 2 | 2024 | 15 | |
| 3 | 2024 | 1 | |
| 4 | 2021 | 93 | |
| 5 | 2019 | 116 | |
| 6 | 2019 | 99 | |
| 7 | 2018 | 7 | |
| 8 | Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trialbreakdown → | 2017 | 257 |
| 9 | 2017 | 10 | |
| 10 | 2017 | 72 | |
| 11 | 2016 | 10 | |
| 12 | Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study | 2016 | 12 |
| 13 | 2015 | 158 | |
| 14 | 2014 | 1 | |
| 15 | 2013 | 34 | |
| 16 | 2013 | 97 | |
| 17 | 2012 | 256 | |
| 18 | 2011 | 21 | |
| 19 | 2007 | 25 | |
| 20 | Salivary oral cancer transcriptome biomarkers (SOCTB) for clinical detection | 2006 | 2 |
About Xuelian Wei
Xuelian Wei is a scholar working on Virology, Infectious Diseases and Nephrology, having authored 33 papers that have together received 2.0k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (20 papers), HIV Research and Treatment (14 papers), HIV/AIDS Research and Interventions (10 papers), HIV-related health complications and treatments (10 papers), Renal Diseases and Glomerulopathies (8 papers), Platelet Disorders and Treatments (3 papers), Pharmacological Effects and Toxicity Studies (3 papers) and Systemic Lupus Erythematosus Research (3 papers). The work is most often cited by research in Virology (1.0k citations), Emergency Medicine (886 citations) and Infectious Diseases (1.6k citations). Xuelian Wei has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Jürgen K. Rockstroh, Andrew Cheng, Kirsten White, Hal Martin, Chloe Orkin, Paul E. Sax, Edwin DeJesus, Diana M. Brainard, Frank A. Post and Joseph Gathe. Their work appears in journals such as Proceedings of the National Academy of Sciences, The Lancet and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.